NYSE:LLY - Eli Lilly and Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $317.00
  • Forecasted Upside: 3.42 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$306.53
▲ +4.03 (1.33%)

This chart shows the closing price for LLY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eli Lilly and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

Analyst Price Target is $317.00
▲ +3.42% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Eli Lilly and in the last 3 months. The average price target is $317.00, with a high forecast of $395.00 and a low forecast of $264.00. The average price target represents a 3.42% upside from the last price of $306.53.

This chart shows the closing price for LLY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 investment analysts is to buy stock in Eli Lilly and. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/27/2022UBS GroupBoost Price TargetOutperform$335.00Low
7/8/2022Morgan StanleyBoost Price TargetOverweight$369.00 ➝ $395.00N/A
7/7/2022BarclaysBoost Price TargetOverweight$333.00 ➝ $355.00N/A
6/1/2022JPMorgan Chase & Co.Boost Price Target$340.00 ➝ $355.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperform$341.00Low
5/2/2022MizuhoBoost Price Target$315.00 ➝ $356.00Low
4/29/2022Morgan StanleyBoost Price Target$364.00 ➝ $369.00High
4/29/2022Wells Fargo & CompanyBoost Price Target$280.00 ➝ $305.00Medium
4/12/2022The Goldman Sachs GroupBoost Price TargetNeutral$234.00 ➝ $264.00Low
4/6/2022Morgan StanleyBoost Price TargetOverweight$265.00 ➝ $364.00High
3/17/2022Bank of AmericaBoost Price Target$300.00 ➝ $315.00Medium
3/10/2022Daiwa Capital MarketsInitiated CoverageOutperform$286.00Medium
2/4/2022MizuhoLower Price TargetBuy$302.00 ➝ $293.00High
2/4/2022Morgan StanleyLower Price TargetOverweight$272.00 ➝ $265.00Medium
1/24/2022Morgan StanleyLower Price TargetOverweight$275.00 ➝ $272.00Low
1/21/2022DZ BankUpgradeHold ➝ Buy$291.00Medium
1/5/2022MizuhoBoost Price Target$272.00 ➝ $302.00High
1/4/2022Wells Fargo & CompanyBoost Price TargetEqual Weight$270.00 ➝ $280.00Low
1/3/2022Sanford C. BernsteinBoost Price TargetMarket Perform$250.00 ➝ $300.00High
12/20/2021Berenberg BankBoost Price TargetBuy$270.00 ➝ $305.00High
12/20/2021BarclaysBoost Price TargetOverweight$280.00 ➝ $325.00High
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$236.00High
12/16/2021MizuhoInitiated CoverageBuy$272.00Low
12/16/2021BMO Capital MarketsBoost Price TargetOutperform$311.00 ➝ $320.00Low
12/16/2021Bank of AmericaBoost Price TargetBuy$285.00 ➝ $300.00Low
12/16/2021JPMorgan Chase & Co.Reiterated RatingBuyLow
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$270.00Low
11/24/2021Truist FinancialBoost Price TargetBuy$262.00 ➝ $301.00Low
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$311.00Medium
10/27/2021MizuhoLower Price TargetBuy$279.00 ➝ $272.00Low
10/11/2021Berenberg BankUpgradeHold ➝ Buy$240.00 ➝ $270.00Low
9/29/2021CitigroupUpgradeNeutral ➝ Buy$210.00 ➝ $265.00High
9/24/2021JPMorgan Chase & Co.Reiterated RatingBuy$300.00Low
8/30/2021CowenBoost Price TargetOutperform$250.00 ➝ $300.00Low
8/9/2021ArgusBoost Price TargetBuy$225.00 ➝ $300.00Medium
8/5/2021DZ BankUpgradeHold ➝ Buy$288.00Low
8/4/2021JPMorgan Chase & Co.Boost Price TargetTop Pick ➝ Overweight$270.00 ➝ $300.00Medium
8/4/2021Morgan StanleyBoost Price TargetOverweight$207.00 ➝ $275.00High
8/4/2021MizuhoBoost Price TargetBuy$250.00 ➝ $279.00High
7/27/2021Truist FinancialInitiated CoverageBuy$262.00Low
7/7/2021MizuhoReiterated RatingBuy$250.00Low
7/6/2021BarclaysBoost Price TargetOverweight$227.00 ➝ $250.00Low
7/2/2021Truist FinancialBoost Price TargetBuy ➝ Buy$225.00 ➝ $262.00Low
6/24/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$245.00 ➝ $300.00High
6/24/2021CowenBoost Price TargetPositive ➝ Outperform$235.00 ➝ $250.00High
6/15/2021JPMorgan Chase & Co.Boost Price TargetOverweight$240.00 ➝ $260.00Low
6/14/2021The Goldman Sachs GroupBoost Price TargetPositive ➝ Conviction-Buy$252.00 ➝ $270.00Low
6/8/2021Truist FinancialReiterated RatingBuy$225.00Medium
4/28/2021Morgan StanleyLower Price TargetOverweight$217.00 ➝ $207.00Medium
4/28/2021MizuhoLower Price TargetBuy$228.00 ➝ $216.00Medium
4/28/2021BarclaysLower Price TargetOverweight$232.00 ➝ $227.00Medium
3/15/2021Truist FinancialBoost Price TargetBuy$215.00 ➝ $225.00High
2/12/2021CowenBoost Price TargetOutperform$195.00 ➝ $235.00Low
2/4/2021Morgan StanleyBoost Price TargetOverweight$190.00 ➝ $217.00Medium
2/1/2021Truist FinancialBoost Price Target$200.00 ➝ $215.00Low
2/1/2021MizuhoBoost Price TargetBuy$222.00 ➝ $228.00Low
2/1/2021BarclaysBoost Price TargetOverweight$190.00 ➝ $232.00Low
1/22/2021Bank of AmericaBoost Price TargetBuy$195.00 ➝ $225.00Medium
1/19/2021MizuhoUpgradeNeutral ➝ Buy$164.00 ➝ $222.00N/A
1/12/2021Truist FinancialBoost Price Target$182.00 ➝ $200.00Medium
12/16/2020MizuhoBoost Price TargetNeutral$156.00 ➝ $164.00High
12/10/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$147.00 ➝ $183.00Medium
11/17/2020MizuhoLower Price TargetNeutral$164.00 ➝ $156.00Low
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$150.00Low
10/28/2020Morgan StanleyLower Price TargetOverweight$176.00 ➝ $170.00Low
10/23/2020Truist FinancialInitiated CoverageBuy$180.00Medium
10/16/2020JPMorgan Chase & Co.Boost Price TargetOverweight$190.00 ➝ $200.00Low
9/29/2020Berenberg BankInitiated CoverageHold$144.00Medium
9/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$149.55 ➝ $176.00High
8/14/2020Morgan StanleyBoost Price TargetEqual Weight$148.00 ➝ $157.00Low
6/29/2020MizuhoBoost Price TargetNeutral$155.00 ➝ $164.00Low
6/19/2020Bank of AmericaReiterated RatingBuy$180.00Low
6/17/2020JPMorgan Chase & Co.Boost Price TargetOverweight$175.00 ➝ $190.00Low
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$182.00High
4/24/2020MizuhoBoost Price TargetBuy$148.00 ➝ $155.00Low
4/24/2020CfraBoost Price TargetHold$146.00 ➝ $167.00Low
4/24/2020Cantor FitzgeraldBoost Price TargetOverweight$156.00 ➝ $185.00Low
4/20/2020UBS GroupDowngradeBuy ➝ Neutral$157.00 ➝ $158.00High
4/19/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
4/15/2020CowenBoost Price TargetOutperform$145.00 ➝ $160.00Medium
4/9/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$148.00Low
4/2/2020MizuhoReiterated RatingHold$148.00Medium
4/2/2020Morgan StanleyLower Price TargetOverweight ➝ Equal Weight$150.00 ➝ $148.00High
3/11/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$168.00Medium
2/27/2020BarclaysInitiated CoverageOverweightHigh
2/18/2020Cantor FitzgeraldReiterated RatingBuy$156.00Low
2/5/2020MizuhoInitiated CoverageNeutral$148.00Low
2/3/2020Cantor FitzgeraldReiterated RatingBuy$156.00Medium
12/30/2019ArgusBoost Price TargetBuy$145.00 ➝ $165.00Low
12/18/2019JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $150.00High
12/18/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$116.00 ➝ $150.00High
12/2/2019Cantor FitzgeraldReiterated RatingBuy$143.00Low
10/17/2019UBS GroupLower Price TargetBuy$134.00 ➝ $133.00Low
10/16/2019Bank of AmericaInitiated CoverageBuy$133.00Low
9/10/2019Bank of AmericaSet Price TargetNeutral$118.00 ➝ $120.00High
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$135.00Low
5/1/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $133.00Low
4/30/2019Cantor FitzgeraldReiterated RatingBuy$143.00Medium
4/23/2019Edward JonesUpgradeHold ➝ Buy$117.49Low
4/22/2019BMO Capital MarketsLower Price TargetOutperform$130.00Medium
4/14/2019BarclaysReiterated RatingBuy$140.00Low
4/11/2019GuggenheimDowngradeBuy ➝ Neutral$125.84Low
3/22/2019Credit Suisse GroupSet Price TargetHold$121.00Low
3/21/2019Bank of AmericaSet Price TargetHold$129.00Low
3/20/2019UBS GroupInitiated CoverageBuy$140.00 ➝ $74.51Low
3/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$140.00Low
2/26/2019CitigroupSet Price TargetHold$124.00Medium
2/8/2019UBS GroupLower Price TargetAverage$107.53 ➝ $100.00Low
2/4/2019Cantor FitzgeraldReiterated RatingBuyLow
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$131.00Low
1/20/2019BarclaysReiterated RatingBuy$130.00Low
12/27/2018ArgusReiterated RatingBuyMedium
12/24/2018BMO Capital MarketsBoost Price TargetOutperform$124.00 ➝ $132.00Low
12/20/2018Morgan StanleySet Price TargetHold$116.00High
12/19/2018BMO Capital MarketsReiterated RatingBuyLow
12/2/2018CitigroupDowngradeBuy ➝ Neutral$113.00Low
11/26/2018CitigroupDowngradeBuy ➝ Neutral$115.00Low
11/7/2018Societe GeneraleSet Price TargetHold$106.00High
10/31/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralMedium
10/23/2018Wolfe ResearchInitiated CoverageMarket Perform$119.00Low
10/17/2018Cantor FitzgeraldReiterated RatingBuy$128.00Medium
10/12/2018BarclaysBoost Price TargetOverweight$112.00 ➝ $120.00Low
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
10/5/2018JPMorgan Chase & Co.Set Price TargetBuy$123.00Low
10/4/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$107.00 ➝ $130.00High
10/3/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$90.00 ➝ $107.00Medium
10/1/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$105.00 ➝ $123.00Low
9/27/2018Cantor FitzgeraldSet Price TargetBuy$110.00Low
9/26/2018JPMorgan Chase & Co.Set Price TargetNot Rated ➝ Overweight$117.00Low
9/18/2018BarclaysReiterated RatingOverweight$107.00 ➝ $112.00Low
9/17/2018Cantor FitzgeraldSet Price TargetBuy$110.00Low
9/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$98.00 ➝ $107.00Medium
7/31/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $102.00Low
7/31/2018SunTrust BanksReiterated RatingBuy$105.00Low
7/25/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$90.00 ➝ $94.00Medium
7/25/2018Credit Suisse GroupBoost Price TargetUnderperform ➝ Underperform$84.00 ➝ $86.00High
7/25/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$80.00 ➝ $90.00High
7/25/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $110.00High
7/25/2018Berenberg BankDowngradeBuy ➝ Hold$99.00High
7/25/2018The Goldman Sachs GroupSet Price TargetNeutral$100.00High
7/24/2018CowenSet Price TargetBuy$105.00High
7/24/2018Cantor FitzgeraldSet Price TargetBuy$100.00High
7/19/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ $89.43$78.00 ➝ $80.00Medium
7/17/2018Cantor FitzgeraldSet Price TargetBuy$100.00Low
7/17/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$86.00 ➝ $90.00Low
7/15/2018Jefferies Financial GroupSet Price TargetBuy$100.00Low
7/13/2018Credit Suisse GroupSet Price TargetHold$84.00Low
7/9/2018Cantor FitzgeraldSet Price TargetBuy$100.00Low
6/22/2018DZ BankReiterated RatingBuy ➝ HoldLow
6/21/2018Credit Suisse GroupBoost Price TargetUnderperform ➝ Underperform$82.00 ➝ $84.00Low
6/11/2018JPMorgan Chase & Co.Set Price TargetBuy$100.00Low
6/7/2018Cantor FitzgeraldInitiated CoverageOverweight$100.00Low
5/22/2018BarclaysSet Price TargetBuy$98.00Low
5/15/2018Credit Suisse GroupSet Price TargetHold$82.00Low
5/10/2018BMO Capital MarketsReiterated RatingHold$78.00Low
4/25/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$79.00 ➝ $78.00Medium
4/24/2018BMO Capital MarketsReiterated RatingHold$79.00Medium
4/22/2018Credit Suisse GroupSet Price TargetHold$80.00Medium
4/18/2018HC WainwrightReiterated RatingBuyLow
4/13/2018BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$74.00 ➝ $79.00Low
4/13/2018Jefferies Financial GroupSet Price TargetBuy$90.00Low
4/4/2018BMO Capital MarketsReiterated RatingSell$74.00Medium
3/23/2018Jefferies Financial GroupReiterated RatingBuy$91.00Medium
2/26/2018Jefferies Financial GroupSet Price TargetBuy$93.00Low
2/26/2018JPMorgan Chase & Co.Set Price TargetBuy$105.00Medium
2/2/2018Credit Suisse GroupReiterated RatingHold$80.00Low
2/1/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$88.00 ➝ $86.00Low
2/1/2018BMO Capital MarketsBoost Price TargetUnderperform ➝ Underperform$73.00 ➝ $74.00Low
1/22/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform$82.00Low
1/16/2018Jefferies Financial GroupSet Price TargetBuy$100.00High
1/16/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral$86.98 ➝ $95.00High
1/5/2018ArgusUpgradeHold ➝ Buy$85.52 ➝ $115.00Medium
12/13/2017Credit Suisse GroupReiterated RatingHoldMedium
12/12/2017BMO Capital MarketsSet Price TargetSell$73.00Low
12/5/2017BMO Capital MarketsSet Price TargetSell$73.00Low
11/21/2017Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $90.00N/A
11/1/2017BMO Capital MarketsSet Price TargetSell$73.00N/A
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/A
10/24/2017BMO Capital MarketsSet Price TargetSell$73.00N/A
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$92.00 ➝ $93.00N/A
10/16/2017BMO Capital MarketsSet Price TargetSell$73.00N/A
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/A
10/13/2017BarclaysBoost Price TargetOverweight$90.00 ➝ $98.00N/A
10/10/2017BMO Capital MarketsBoost Price TargetUnderperform$71.00 ➝ $73.00N/A
10/10/2017Credit Suisse GroupDowngradeOutperform ➝ Neutral$84.23 ➝ $88.00N/A
10/6/2017Morgan StanleySet Price TargetHold$86.00N/A
10/5/2017The Goldman Sachs GroupReiterated RatingBuy$92.00 ➝ $95.00N/A
10/4/2017CowenReiterated RatingBuy$95.00Low
9/28/2017BMO Capital MarketsReiterated RatingSell$71.00Low
9/15/2017Morgan StanleyReiterated RatingHold$86.00Low
9/11/2017Jefferies Financial GroupReiterated RatingBuy$89.00 ➝ $89.00Low
9/8/2017Piper Jaffray CompaniesReiterated RatingOverweight$103.00 ➝ $105.00Low
9/6/2017BMO Capital MarketsReiterated RatingUnderperform$73.00 ➝ $71.00Low
8/31/2017Jefferies Financial GroupReiterated RatingBuy$89.00Medium
8/31/2017Piper Jaffray CompaniesReiterated RatingBuy$103.00Low
8/31/2017SVB LeerinkReiterated RatingHoldLow
8/24/2017Jefferies Financial GroupReiterated RatingBuy$94.00 ➝ $89.00Low
8/16/2017BMO Capital MarketsReiterated RatingSell$73.00High
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 24 very positive mentions
  • 52 positive mentions
  • 10 negative mentions
  • 5 very negative mentions
1/11/2022
  • 11 very positive mentions
  • 66 positive mentions
  • 14 negative mentions
  • 4 very negative mentions
2/10/2022
  • 19 very positive mentions
  • 60 positive mentions
  • 6 negative mentions
  • 15 very negative mentions
3/12/2022
  • 15 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 8 very negative mentions
4/11/2022
  • 16 very positive mentions
  • 55 positive mentions
  • 4 negative mentions
  • 11 very negative mentions
5/11/2022
  • 26 very positive mentions
  • 66 positive mentions
  • 6 negative mentions
  • 10 very negative mentions
6/10/2022
  • 17 very positive mentions
  • 36 positive mentions
  • 6 negative mentions
  • 8 very negative mentions
7/10/2022
  • 8 very positive mentions
  • 55 positive mentions
  • 9 negative mentions
  • 8 very negative mentions
8/9/2022

Current Sentiment

  • 8 very positive mentions
  • 55 positive mentions
  • 9 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Eli Lilly and logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $306.53
Low: $302.06
High: $306.53

50 Day Range

MA: $315.68
Low: $288.07
High: $331.60

52 Week Range

Now: $306.53
Low: $220.20
High: $335.33

Volume

3,068 shs

Average Volume

2,537,060 shs

Market Capitalization

$291.26 billion

P/E Ratio

48.89

Dividend Yield

1.30%

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?

The following sell-side analysts have issued reports on Eli Lilly and in the last twelve months: Argus, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Cowen Inc, Daiwa Capital Markets, DZ Bank AG, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Sanford C. Bernstein, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and?

17 Wall Street analysts have set twelve-month price targets for Eli Lilly and in the last year. Their average twelve-month price target is $317.00, suggesting a possible upside of 3.4%. Morgan Stanley has the highest price target set, predicting LLY will reach $395.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $264.00 for Eli Lilly and in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and?

Eli Lilly and currently has 3 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LLY will outperform the market and that investors should add to their positions of Eli Lilly and.
View the latest ratings for LLY.

What other companies compete with Eli Lilly and?

How do I contact Eli Lilly and's investor relations team?

Eli Lilly and's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is [email protected] The official website for Eli Lilly and is www.lilly.com. Learn More about contacing Eli Lilly and investor relations.